CREATININE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 113.0 | -1.2 | 1 | 3 | 59.0 | 0 | 0.5 |
- CAS
- 60275
- UNII
- AYI8EX34EU
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 69 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00005766 | Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis | Phase 2 | Completed | |
| NCT02280070 | 2013-09-01 | RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301). | Phase 2 | Recruiting |
| NCT01909141 | 2013-08-01 | Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS | Phase 0 | Completed |
| NCT00323128 | 2006-05-01 | Validation of Serum Creatinine Dosage and Renal Clearance | Phase 1 | Completed |
| NCT00178425 | 2005-01-01 | PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients | Phase 4 | Completed |
(Browse) Purchasable Analogs in ZINC
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Auricular (otic) | Solution | 0.5% |
| Im - Iv | Injection | 0.8% |
| Im - Iv - Sc | Injection | |
| Intra-Articular | Injection | 0.8% |
| Intra-Articular | Injection, Sustained Action | |
| Intrabursal | Injection | |
| Intradermal | Injection, Sustained Action | |
| Intralesional | Injection | 0.8% |
| Intralesional | Injection, Sustained Action | |
| Intramuscular | Injection | 0.5% |
| Intramuscular | Injection, Sustained Action | |
| Intrasynovial | Injection | 0.8% |
| Intrasynovial | Injection, Sustained Action | |
| Ophthalmic | Solution | 0.5% |
| Ophthalmic | Solution, Drops | 0.2% |
| Soft Tissue | Injection | 0.8% |
| Topical | Emulsion, Cream |